Paediatric 🧒 cardiac drug doses by weight
Calculates weight-based doses for children, capped at the adult maximum: emergency cardiac drugs and energies (adenosine, amiodarone, procainamide, lidocaine, epinephrine, atropine, magnesium, calcium, bicarbonate, glucose, cardioversion and defibrillation), oral and IV beta-blockers and calcium-channel blockers with the age from which each can be used and the arrhythmias they treat, the hypercyanotic (tet) spell, continuous infusions (epinephrine, norepinephrine, dopamine, dobutamine, milrinone, alprostadil, amiodarone): pressing a drug opens its usual vial made up to a 50 mL syringe (e.g. dopamine 200 mg, dobutamine 250 mg, norepinephrine 4 mg; amiodarone in glucose 5% only, never saline) with the pump rate in mL/h, anti-failure medicines (furosemide, spironolactone, captopril, enalapril, carvedilol, metoprolol, bisoprolol, ivabradine, sacubitril/valsartan, digoxin by age), and thrombolysis and anticoagulation with their indications, including central line thrombosis and a blocked line. Weight can be estimated from age.
- Adenosine (SVT), 1st dose0.1 mg/kg rapid IV/IO push, max 6 mgTwo-syringe rapid flush (5–10 mL saline) as close to the heart as possible; record the ECG.AHA PALS
- Adenosine, 2nd dose0.2 mg/kg, max 12 mgAHA PALS
- Amiodarone (perfusing SVT/VT)5 mg/kg IV over 20–60 min, max 300 mgMay repeat to 15 mg/kg/day. Expert advice: hypotension and bradycardia; do not combine with procainamide.AHA PALS
- Amiodarone (VF/pVT arrest)5 mg/kg IV/IO bolus, max 300 mgAfter the 3rd shock; repeat up to 3 doses.AHA PALS
- Procainamide (SVT/VT)15 mg/kg IV over 30–60 min, max 1 gStop for hypotension or QRS widening > 50%.AHA PALS
- Lidocaine (VF/pVT, alternative to amiodarone)1 mg/kg IV/IO loading bolus, max 100 mg; then infusion 20–50 µg/kg/minPALS gives one loading dose; repeat 1 mg/kg only if the infusion starts more than 15 min after the first bolus. The adult ACLS scheme (1–1.5 mg/kg, then 0.5–0.75 mg/kg every 5–10 min, total 3 mg/kg) is for adult-sized adolescents.AHA PALS / ACLS
- Epinephrine (arrest, bradycardia)0.01 mg/kg IV/IO (0.1 mL/kg of 0.1 mg/mL), max 1 mgEvery 3–5 min. Endotracheal 0.1 mg/kg (0.1 mL/kg of 1 mg/mL) only without IV/IO access.AHA PALS
- Atropine (vagal bradycardia, AV block)0.02 mg/kg IV/IO, max 0.5 mg per doseMay repeat once.AHA PALS
- Magnesium sulphate (torsades)25–50 mg/kg IV over 10–20 min, max 2 gFaster in pulseless torsades.AHA PALS
- Calcium chloride 10%20 mg/kg (0.2 mL/kg) slow IV/IO, max 1 gHyperkalaemia, hypocalcaemia, calcium-channel blocker toxicity. Central line preferred.AHA PALS
- Calcium gluconate 10%60 mg/kg (0.6 mL/kg) slow IV/IO, max 3 gAHA PALS
- Sodium bicarbonate1 mEq/kg slow IV/IOHyperkalaemia, sodium-channel blocker toxicity; not routine in arrest.AHA PALS
- Glucose (hypoglycaemia)0.5–1 g/kg IV/IO (D10W 5–10 mL/kg)AHA PALS
- Synchronised cardioversion0.5–1 J/kg, then 2 J/kgSedate if possible; do not delay in an unstable child.AHA PALS
- Defibrillation (VF/pVT)2 J/kg, then 4 J/kg, up to 10 J/kg or the adult doseAHA PALS
- Topjian AA, et al. Part 4: Pediatric basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2020;142(suppl 2):S469-S523.
- American Heart Association. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 8: Pediatric advanced life support. Circulation 2025;152(suppl 2).
- Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and Lung Transplantation guidelines for the management of pediatric heart failure: executive summary. J Heart Lung Transplant 2014;33:888-909.
- Shaddy RE, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007;298:1171-1179.
- Shaddy R, et al. Sacubitril/valsartan in pediatric heart failure (PANORAMA-HF): a randomized, multicenter, double-blind study. Circulation 2024;150:1756-1766.
- Johns Hopkins Hospital. The Harriet Lane Handbook, 23rd ed. Elsevier; 2023 (formulary).
- Brugada J, Blom N, Sarquella-Brugada G, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace 2013;15:1337-1382.
- Bonnet D, Berger F, Jokinen E, Kantor PF, Daubeney PEF. Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure. J Am Coll Cardiol 2017;70:1262-1272.
- Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e737S-e801S.
- Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018;2:3292-3316.
- Park MK, Salamat M. Park's Pediatric Cardiology for Practitioners, 7th ed. Elsevier; 2020. Tetralogy of Fallot: hypercyanotic spells.